Deal-happy Valeant eyes more buyouts, 'merger of equals'

Months after spending $8.7 billion on Bausch + Lomb, Canada's Valeant Pharmaceuticals ($VRX) is hardly done dealmaking, CEO Michael Pearson said. The chief told analysts Valeant is on the lookout for cash deals to expand its pipeline and is keeping its ears open to a "merger of equals." Article